For medical or scientific enquiries or other enquiries, please contact us here:

Contact

History

What we have achieved.

Our tradition of innovations is long. We have been inventing therapeutic solutions for the unmet needs of patients and healthcare providers for more than 110 years, always following the principle of our founder Friedrich Merz: “Do it differently than the others.”
In order to meet patients’ needs even better and to reach even more people by driving responsible growth, Merz Therapeutics, part of the Merz Group, has been operating as an individual business since 2020.

At a glance

History of therapeutic innovations

Launch of Contractubex®

Prevention of scars, for fresh or older scars and keloids, promoting the normal wound healing process, anti-inflammat ...

Read More
1959

Launch of Hepa-Merz®

For the treatment of chronic liver diseases with insufficient hepatic detoxification (e.g. in liver cirrhosis) and it ...

Read More
1969

Launch of PK-Merz®

For the treatment of symptoms of Parkinson‘s disease, such as rigor, tremor and hypo or akinesia, drug-induced extrap ...

Read More
1970

Launch of Pantogar®

Hair and nail therapeutic agent for the treatment of various forms of diffuse hair loss and improvement in hair growt ...

Read More
1978

Introduction of a new formula of Memantine

First active compound worldwide for the treatment of moderate to severe Alzheimer’s disease

2002

Launch of a new formula of botulinum neurotoxin type A

German approval for the treatment of blepharospasm and cervical dystonia in adults

2005

Botulinum neurotoxin type A

EU approval for the treatment of post-stroke upper limb spasticity in adults

2009

Botulinum neurotoxin type A

US approval for the treatment of adults with cervical dystonia and blepharospasm (pre-treated with onabotulinumtoxina ...

Read More
2010

Cuvposa®

FDA-approved treatment for the treatment of chronic severe drooling in pediatric patients with neurological condition ...

Read More
2010

Launch of ProlarynTM gel and plus

Proven injectable implants indicated for the treatment of vocal fold insufficiency, providing both short-term and lon ...

Read More
2013

Botulinum neurotoxin type A

US approval for the treatment of adult patients with upper limb spasticity

2015

Botulinum neurotoxin type A

US approval for the treatment of adults with chronic sialorrhea

2018

Botulinum neurotoxin type A

  • EU approval for the treatment of chronic sialorrhea in adults
  • US approval for first-li ...
Read More
2019

Start of Merz Therapeutics as an own business

Start of Merz Therapeutics as a dedicated business within the Merz Group committed to serving the unmet needs of pati ...

Read More
2020

Botulinum neurotoxin type A

  • Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the ...
Read More
2020

Botulinum neurotoxin type A

  • Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the ...
Read More
2021